Roger Gomis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates Results showing the clinical utility of the test have been published in Lancet Oncology and the Journal of National Cancer Institute The MAF Test® is now available to oncologists and pathologists in United Kingdom and Ireland and will benefit an estimated 56,000 new patients each year This agreement follows Inbiomotion’s recent distribution partnerships for Spain and Portugal with Palex Medical a

Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed each year. In cases where the tumour remains localised in the breast, survival rates are remarkably high, at around 90%.

MAFTEST analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST for selection of early-stage breast cancer patients that benefit from adjuvant

/PRNewswire/ -- Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III)...

BARCELONA, Spain, July 13, 2022 /PRNewswire/ -- On 13 May 2022, the conformity assessment for the unique in vitro diagnostic medical device MAFTEST developed by Inbiomotion was completed and